Investor Bratton Douglas K
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Bratton Douglas K . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-02-13 13G/A AQST / Aquestive Therapeutics, Inc. 10,117,434 10,077,434
2024-02-13 13G/A DNLI / Denali Therapeutics Inc. 7,000,882 5,750,882
2023-05-03 13D/A MDWT / Midwest Holding Inc. 222,222,222 445,171
2023-02-13 13G/A DNLI / Denali Therapeutics Inc. 7,845,189 7,000,882
2022-12-21 13G / ALTITUDE ACQUISITION CORP A 70,573 0
2022-12-13 13G / ALTITUDE ACQUISITION CORP A 70,573
2022-11-18 13G AMAO / American Acquisition Opportunity Inc - Class A 0
2022-02-14 13G/A DNLI / Denali Therapeutics Inc. 12,348,784 7,845,189
2022-02-11 13G/A AQST / Aquestive Therapeutics, Inc. 11,611,754 10,117,434
2021-02-12 13G/A DNLI / Denali Therapeutics Inc. 20,415,535 12,348,784
2021-02-09 13G/A AQST / Aquestive Therapeutics, Inc. 11,585,054 11,611,754
2020-05-04 13D MDWT / Midwest Holding Inc. 222,222,222
2020-02-12 13G/A AQST / Aquestive Therapeutics, Inc. 11,578,379 11,585,054
2020-02-11 13G/A DNLI / Denali Therapeutics Inc. 20,574,298 20,415,535
2019-02-13 13G AQST / Aquestive Therapeutics, Inc. 11,578,379
2018-02-13 13G DNLI / Denali Therapeutics Inc. 20,574,298
2018-02-07 13D/A JUNO / Juno Therapeutics, Inc. 7,628,282 5,433,301
2017-11-08 13D/A JUNO / Juno Therapeutics, Inc. 9,348,799 7,628,282
2017-07-18 13D/A JUNO / Juno Therapeutics, Inc. 9,348,799 9,348,799
2017-07-17 13D/A JUNO / Juno Therapeutics, Inc. 17,348,799 9,348,799
2016-03-03 13D/A JUNO / Juno Therapeutics, Inc. 25,988,799 17,348,799
2015-06-25 13D/A JUNO / Juno Therapeutics, Inc. 25,988,799
2014-12-29 13D JUNO / Juno Therapeutics, Inc. 27,084,525